Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2.

Publication Type:

Journal Article

Source:

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, Volume 3, Issue 9, p.1026-31 (2008)

Keywords:

2008, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Protein Kinase Inhibitors, Public Health Sciences Division, Quinazolines, Receptor, Epidermal Growth Factor, Survival Rate, Treatment Outcome

Abstract:

This phase II study (S0341) evaluated the efficacy and tolerability of single-agent erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) of 2. Exploratory analyses of a number of biomarkers relating to epidermal growth factor receptor pathway activation were also performed.